Search

everythinglearnresearchcommunity

for

Search:↓

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

The protein ER71/ETV2 helps regrow hair after chemotherapy by improving the growth of new blood vessels.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

A scalp-cooling system effectively prevents hair loss in breast cancer patients treated with eribulin.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

RCS-01 cell therapy is safe and improves skin gene expression.

Eph receptors and ephrins may be promising targets for treating diseases, but more understanding is needed for effective and safe therapies.

ATR12-351 ointment safely delivers LEKTI protein to the skin, reducing enzyme activity in Netherton syndrome.

RCS-01 is safe and may help rejuvenate aging skin.

RCS-01 therapy is safe and may improve skin structure by affecting gene expression.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.

CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.

The regenerative medicine industry saw business growth with new partnerships, clinical trials, and financial investments.

The new drug delivery system effectively targets lung cancer cells.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

New lipid/fiber microplexes improve mRNA therapy for degenerative diseases by enhancing cell function and treatment effectiveness.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

Ritlecitinib is safe and may effectively treat alopecia areata.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.

ERβ has potential in treating prostate cancer and neurodegenerative diseases, but human studies are needed before clinical use.

Recombinant human epidermal growth factor is versatile, effective, and safe for long-term skin and mucosal treatments.